
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1069 | 1066 | 1013 | 1130 | 1491 | 1882 |
Fund Return | 6.87% | 6.59% | 1.26% | 4.16% | 8.32% | 6.53% |
Place in category | 222 | 190 | 391 | 327 | 175 | 93 |
% in Category | 43 | 39 | 75 | 71 | 51 | 39 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
AllianzIncome Growth P H2EUR | 50.57B | 2.43 | 2.96 | 5.70 | ||
AllianzIncome Growth A H2EUR | 50.57B | 2.38 | 2.42 | 5.08 | ||
AllianzIncome Growth IT H2EUR | 50.57B | 2.41 | 3.11 | 5.79 | ||
AllianzIncome Growth CT H2EUR | 50.57B | 2.31 | 1.60 | 4.24 | ||
AllianzIncome Growth RT H2EUR | 50.57B | 2.43 | 2.93 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Allianz Europe Equity Growth A EUR | 3.04B | 6.71 | 3.28 | 5.63 | ||
Allianz Europe Equity Growth AT EUR | 3.04B | 6.72 | 3.28 | 5.63 | ||
Allianz Europe Equity Growth PT EUR | 3.04B | 6.87 | 4.16 | 6.53 | ||
Allianz Europe Equity Growth I EUR | 3.04B | 6.87 | 4.20 | 6.57 | ||
Allianz Europe Equity Growth IT EUR | 3.04B | 6.87 | 4.20 | 6.57 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
ASML Holding | NL0010273215 | 7.80 | 645.50 | +2.14% | |
SAP | DE0007164600 | 5.64 | 242.550 | +1.63% | |
Novo Nordisk B | DK0062498333 | 5.09 | 507.6 | -4.32% | |
DSV | DK0060079531 | 3.99 | 1,407.0 | +1.19% | |
Partners Group | CH0024608827 | 3.76 | 1,279.50 | +0.79% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Neutral |
Technical Indicators | Sell | Sell | Sell |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review